Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renervix is an ophthalmic gel medical device developed by Alfa Intes for corneal neuroprotection and nerve regeneration. The formulation contains 0.3% cross-linked hyaluronic acid, which provides prolonged lubrication and viscoelastic support by adhering to the corneal surface for an extended period. It is enriched with a nutrient complex including vitamin B12 (cyanocobalamin) to accelerate corneal re-epithelialization, vitamin B6 (pyridoxamine) to stimulate the regrowth of corneal nerve endings, and taurine to support nerve health and neutralize oxidative stress in epithelial cells. Renervix is primarily indicated to support the physiological repair of the cornea and promote reinnervation following anterior segment surgery or corneal abrasions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renervix.